JPMorgan Chase & Co. Has Lowered Expectations for Cytokinetics (NASDAQ:CYTK) Stock Price

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its target price reduced by analysts at JPMorgan Chase & Co. from $103.00 to $100.00 in a report released on Friday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 97.01% from the stock’s current price.

A number of other research analysts have also recently issued reports on the company. Citigroup lifted their target price on Cytokinetics from $99.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. HC Wainwright reissued a “buy” rating and set a $140.00 target price on shares of Cytokinetics in a research note on Monday, October 19th. Wall Street Zen raised shares of Cytokinetics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. William Blair initiated coverage on shares of Cytokinetics in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Finally, Royal Bank Of Canada raised their price target on shares of Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.50.

View Our Latest Research Report on Cytokinetics

Cytokinetics Stock Performance

Shares of CYTK stock opened at $50.76 on Friday. The stock’s fifty day moving average price is $61.89 and its two-hundred day moving average price is $69.46. The company has a market cap of $7.07 billion, a PE ratio of -8.40 and a beta of 0.45. Cytokinetics has a fifty-two week low of $50.32 and a fifty-two week high of $88.31.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.43) by $0.06. The business had revenue of $47.56 million during the quarter, compared to the consensus estimate of $41.88 million. During the same quarter in the previous year, the business posted ($2.55) EPS. The company’s revenue for the quarter was up 2356.5% on a year-over-year basis. On average, equities analysts predict that Cytokinetics will post -5.85 EPS for the current fiscal year.

Insider Transactions at Cytokinetics

In related news, CEO Robert Blum sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $53.53, for a total value of $401,475.00. Following the completion of the transaction, the chief executive officer owned 278,544 shares in the company, valued at $14,910,460.32. This trade represents a 2.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B. Parshall sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $54.73, for a total transaction of $273,650.00. Following the completion of the transaction, the director owned 5,784 shares of the company’s stock, valued at approximately $316,558.32. This trade represents a 46.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 201,032 shares of company stock valued at $13,320,502. Company insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

Institutional investors have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC bought a new position in shares of Cytokinetics during the second quarter valued at $36,000. Physician Wealth Advisors Inc. lifted its holdings in shares of Cytokinetics by 810.2% during the third quarter. Physician Wealth Advisors Inc. now owns 446 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 397 shares during the period. V Square Quantitative Management LLC grew its stake in shares of Cytokinetics by 71.5% in the third quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 191 shares during the last quarter. Manchester Capital Management LLC bought a new stake in shares of Cytokinetics in the third quarter worth $43,000. Finally, Allworth Financial LP grew its stake in shares of Cytokinetics by 35.6% in the third quarter. Allworth Financial LP now owns 732 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 192 shares during the last quarter.

About Cytokinetics

(Get Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Further Reading

Analyst Recommendations for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.